Summary of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings on May 17, 2018

May 17, 2018 - By Nell Hawkins

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Corporate Logo

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Total analysts of 5 have positions in Adamis Pharma (NASDAQ:ADMP) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 4, 2017 according to StockzIntelligence Inc Adamis Pharma has 5 analyst reports. On Friday, March 23 the firm has “Buy” rating given by B. Riley & Co. On Monday, May 14 the firm has “Buy” rating given by Maxim Group. On Monday, May 14 the rating was maintained by FBR Capital with “Buy”. On Monday, December 4 the rating was maintained by Raymond James with “Buy”. Listed here are Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) PTs and latest ratings.

14/05/2018 Broker: FBR Capital Rating: Buy New Target: $6.2500 Maintain
14/05/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $10 Maintain
23/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7 Initiates Coverage On
23/03/2018 Broker: B. Riley & Co Old Rating: Buy New Rating: Buy Old Target: $7.5 New Target: $6.25 Maintain
04/12/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Maintain

ADMP is touching $4.16 during the last trading session, after increased 2.18%.Currently Adamis Pharmaceuticals Corporation is downtrending after 20.00% change in last May 17, 2017. ADMP has 146,478 shares volume. ADMP underperformed the S&P 500 by 31.55%.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States.The firm is worth $139.03 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease.Last it reported negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

A couple more Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were posted by: which released on May 10, 2018 “Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update”, also on May 14, 2018 posted “Adamis Pharmaceuticals: Paging Dr. Carlo”, the next is “Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences …” on April 19, 2018. has article titled “Adamis Keeps Us Waiting: April Update”.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.